Frontlight ResearchEarly access
Active, not recruitingNo phase
Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease
Key facts
- Who runs it
- Columbia University
- Where
- Birmingham, Boston, Chapel Hill, Charleston, Chicago, Denver, Los Angeles, New York, and Salt Lake City, United StatesSee the 9 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 286 people enrolled
- Started
- 23 Mar 2022
- Expected to end
- Jan 2027
- Type of study
- Observational, 2 groups
- Record updated
- 16 January 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Males and females aged 18 years and older
- Patients with known Alpha-1 Anti-trypsin deficiency (PiZZ)
- Be an existing member of the Alpha-1 Foundation Clinical Cohort (Alpha-1 Foundation Research Registry)
- Willingness to perform study procedures of Chest CT, blood biomarker determination, questionnaire completion, and lung function testing
Who cannot take part
- Previous lung or liver transplantation or currently on the transplant list
- COPD exacerbation or other pulmonary infection within 6 weeks of baseline visit
- AATD non-PiZZ status, including carriers
- Pregnancy at the time of the screening visit
Where in United States
- University of Alabama at BirminghamBirmingham, United States
- Boston UniversityBoston, United States
- University of North CarolinaChapel Hill, United States
- Medical University of South CarolinaCharleston, United States
- University of ChicagoChicago, United States
- National Jewish HealthDenver, United States
- University of California, Los AngelesLos Angeles, United States
- Columbia UniversityNew York, United States
- University of UtahSalt Lake City, United States
About the trial
What the trial wants to find out
Alpha-1 Anti-trypsin Deficiency (AATD) is a genetic disease with lung and liver disease presentations. The purpose of this study is to examine the density of the lung as measured by chest computed tomography (CT) and determine if existing emphysema predicts changes in the rate of subsequent emphysema or changes in CT, serum or plasma biomarkers of interest. The overarching goal is to develop biomarkers that can be used in interventional trials since lung function changes do not typically inform disease progression in AATD.
The 2 groups in the trial
- Moderate to Advanced Emphysema
Patients with moderate or advanced Emphysema as measured by baseline inspiratory PERC-15 below the study median
- Minimal Emphysema
Patients with minimal emphysema as measured by baseline inspiratory PERC-15 above the study median
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease - Alpha-1 Biomarker Research Consortium (A1BC)
- Record updated
- 16 January 2026